Sessions

INNOVATION HUBS FOR GENE THERAPIES: FOSTERING PARTNERSHIPS FOR ADVANCED THERAPIES

INNOVATION HUBS FOR GENE THERAPIES: FOSTERING PARTNERSHIPS FOR ADVANCED THERAPIES

31 Aug 2022
15:30
SPONSORED BY
London Advanced Therapies

Collaboration and partnership working are vital in progressing a gene therapy from bench research to commercialisation and patient benefit.

A new network of Innovation Hubs for Gene Therapies was launched in 2021 through an £18m investment from LifeArc and the Medical Research Council (MRC), with support from the Biotechnology and Biological Sciences Research Council (BBSRC).

This session will explore the network’s collaborative approach to addressing a key bottleneck in the translation of novel gene therapies, namely academic access to GMP-grade viral vectors for early-phase clinical trials. In a complex and rapidly evolving industry, how can we build successful partnerships to ensure patients benefit from new therapies? From balancing competing interests to building trust, the panel we’ll discuss the challenges and benefits of collaborative working in this space, including:

  • Building relationships with academic and industry partners
  • Leveraging external knowledge for process development and innovation
  • The importance of collaborative approaches to address the increasing demand for skills and talent in the advanced therapies sector
15:30:  CHAIR’S INTRODUCTION
Mimoun Azzouz, Director of GTIMC, University of Sheffield
15:40: PRESENTATION – OVERVIEW OF THE INNOVATION HUBS FOR GENE THERAPY
Catriona Crombie, Associate Director of Technology Transfer, LifeArc
15:55:  PANEL DISCUSSION WITH Q&A
Speakers:
  • John Liddell, Chief Technologist, CPI
  • Catriona Crombie, Associate Director of Technology Transfer, LifeArc
  • Dr Jonathan Appleby Chief Scientific Officer, Cell and Gene Therapy Catapult

Speakers

Mimoun Azzouz
Director of GTIMC
University of Sheffield
John Liddell
Chief Technologist
CPI
Catriona Crombie
Associate Director of Technology Transfer
LifeArc
Jonathan Appleby
Chief Scientific Officer
Cell and Gene Therapy Catapult